Journal Article

A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients

Arai, Daisuke, Yasuda, Hiroyuki, Ohgino, Keiko, Ishioka, Kota, Soejima, Kenzo, Tani, Tetsuo, Yoda, Satoshi, Satomi, Ryosuke, Ikemura, Shinnosuke, Naoki, Katsuhiko, Sato, Takashi, Nakayama, Sohei, Terai, Hideki

2019

Overview

BackgroundNo consensus has been reached regarding the treatment order and timing of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and cytotoxic chemotherapy administration for EGFR mutation-positive non-small cell lung cancer (NSCLC) patients.MethodsIn this phase II trial, chemotherapy-naïve patients harboring activating EGFR mutations with stage IIIB/IV or post-surgical recurrent non-squamous NSCLC were enrolled. Patients were treated with erlotinib induction at 150 mg/day for 3 months. This was followed by cytotoxic chemotherapy with platinum plus pemetrexed, with or without bevacizumab, when the induction erlotinib achieved a CR or PR. The primary end point was the 1-year progression-free survival (PFS) rate, while the secondary end points were the response rate (RR), PFS, safety, and overall survival (OS).ResultsTwenty patients were enrolled in this study. The median age was 63 years. Eighteen patients had stage IV disease, and 2 patients had recurrent disease. Eleven patients achieved a PR after induction of erlotinib and 9 out of 11 patients were switched to chemotherapy. The 1-year PFS rate was 45.0% (90% CI 26.8–63.2), the overall RR was 55.0%, and the median PFS was 10.7 months in the intention-to-treat (ITT) population. Grade 3–4 adverse events were reported for 40% of the patients, including patients with leukopenia (10%), neutropenia (20%), and interstitial pneumonitis, bacterial pneumonia, rash, and nausea (all 5%).ConclusionsThe primary end point of this study was not achieved. However, the therapy was well tolerated and may be a treatment option for a future study with patients responsive to short-term erlotinib treatment.Clinical trials registration numberUMIN ID: 000013125.

• Publisher: Springer Nature B.V
• Subject: Bevacizumab / Chemotherapy / Clinical trials / Cytotoxicity / Enzyme inhibitors / Epidermal growth factor / Epidermal growth factor receptors / Immunotherapy / Inhibitor drugs / Leukopenia / Lung cancer / Monoclonal antibodies / Mutation / Nausea / Neutropenia / Non-small cell lung carcinoma / Patients / Platinum / Pneumonitis / Protein-tyrosine kinase receptors / Targeted cancer therapy